Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood α-Synuclein

NCT02281474 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT02281474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02281474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood α-Synuclein
Lead sponsor
Georgetown University
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2014
Completion date
Not reported
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse lewy body disease, parkinson's disease, parkinson's disease dementia